Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Get the latest international news and world events from around the world.

Log in for authorized contributors

Tumor-Infiltrating Clonal Hematopoiesis and Pan-Cancer Prognosis in Patients With Solid Tumors

Tumor-infiltrating clonal hematopoiesis was detected in 18% of patients with solid tumors and associated with older age, prior cytotoxic chemotherapy, and reduced overall survival, especially in breast cancer.

This retrospective cohort study investigated the association of TI-CH with clinical factors and its impact on OS in patients with solid tumors. The prevalence of TI-CH in this patient cohort was higher than in treatment-naive cohorts but lower than that in cohorts with higher rates of cytotoxic chemotherapy and radiotherapy. In addition, the prevalence of TI-CH was higher in patients with MSI-high colorectal tumors than in those with MSS colorectal tumors. Analysis of clinical factors revealed that each decade of increasing age and a history of cytotoxic chemotherapy were significantly associated with higher odds of TI-CH. Although TI-CH was associated with worse OS in the whole cohort (pan-cancer analysis), this outcome was most pronounced in patients with breast tumors. Furthermore, TI-CH of GATA2 in the whole cohort and TI-CH of TET2 in patients with breast tumors had the most prominent associations with worse OS.

The accumulation of somatic variants in hematopoietic stem cells with age provides a competitive advantage, leading to CHIP.2 Additionally, cytotoxic chemotherapy induces gene-specific clonal expansion by allowing clones with variants in DNA damage response genes (eg, TP53, PPM1D) to outcompete other clones because such variants are associated with chemoresistance.25 The TI-CH prevalence in our study was intermediate between treatment-naive and treatment-experienced cohorts. It was higher than in the former due to prior therapy and lower than in the latter owing to reduced exposure to cytotoxic chemotherapy and radiotherapy. This finding is notable given this study cohort’s older age, a known factor for increasing CHIP prevalence.6, 7 Furthermore, we found that TI-CH prevalence was higher in patients with MSI-high colorectal tumors than in those with MSS colorectal tumors. To our knowledge, this finding has not been previously reported.

Cerebral Amyloid Angiopathy

Cerebral amyloid angiopathy is a major cause of hemorrhagic stroke, a frequent contributor to age-related cognitive impairment, and a key component in adverse responses to beta-amyloid (Aβ) immunotherapy. Defined by pathological deposition of Aβ in the small blood vessels of the brain, cerebral amyloid angiopathy is most often diagnosed on the basis of magnetic resonance imaging studies showing multiple hemorrhages or leptomeningeal blood products within or overlying the cerebral cortex. The disorder typically manifests as hemorrhagic stroke or as a contributing factor to cognitive decline and, less commonly, with transient focal neurologic symptoms or a cerebral inflammatory autoimmune syndrome.

How Many Satellites are There in Space?

A satellite is any object that orbits another body in space. Earth’s only natural satellite is the Moon. Every other satellite around Earth, more than 14,000 of them as of early 2026, is artificial. The first one was launched in October 1957 by the Soviet Union; recent ones are reaching orbit at a rate of roughly 60 per week, almost all of them part of SpaceX’s Starlink constellation. The orbital environment around Earth has changed more in the last six years than in the previous sixty, and the trajectory of that change is what makes the satellite question worth revisiting in 2026.

Scientists Say This Simple Supplement May Actually Reverse Heart Disease

Scientists in Japan say a common supplement may actually help “unclog” certain diseased heart arteries from the inside out.

A simple food supplement sold in Japan may have helped reverse a dangerous form of heart disease that often resists standard treatment, according to researchers at Osaka University. The findings, originally published in the European Heart Journal, continue to attract attention because they describe something rarely seen in cardiology: clogged heart arteries becoming noticeably clearer after a nutritional intervention rather than conventional cholesterol lowering alone.

Scientists target a hidden form of heart disease.

Reprogramming myeloid crosstalk overcomes immune resistance in colorectal cancer

Immunotherapy resistance remains a significant clinical challenge in the treatment of colorectal cancer. A recent study by Mount Sinai researchers, published in Cell Reports Medicine, reveals that overcoming this resistance requires more than just activating cancer-fighting T cells; it depends on restoring crucial communication between T cells and myeloid cells, specifically macrophages. Using advanced preclinical models and single-cell analyses, the research team identified exhausted T cells and immunosuppressive macrophages as key drivers of treatment failure. To counter this, they tested a novel combination therapy that targets multiple immune checkpoint proteins (PD-1, CTLA-4, and LAG3) alongside TREM2, a marker found on suppressive macrophages. By successfully reprogramming the tumor microenvironment to simultaneously reinvigorate T cells and neutralize suppressive macrophages, this combination strategy achieved up to 100% tumor clearance in mismatch repair-deficient cancer models and over 70% clearance in typically resistant mismatch repair-proficient models. Furthermore, the approach established long-lasting immune memory against cancer recurrence, highlighting the profound clinical potential of rationally designed combination immunotherapies that address both T cell dysfunction and the suppressive tumor environment.

Mestrallet et al. show that T cell-myeloid interactions determine response to PD-1 blockade in colorectal cancer. Targeting TREM2 macrophages together with LAG3, CTLA4, and PD-1 reprograms the tumor microenvironment and drives antitumor immunity, achieving up to 100% tumor clearance in mismatch repair-deficient and 70% in mismatch repair-proficient models.

/* */